On Thursday, TD Cowen made an adjustment to Danaher Corporation's (NYSE:DHR) financial outlook by reducing the price target from $315.00 to $260.00. Despite this change, the firm has maintained a Buy rating on the company's shares. The adjustment follows Danaher's latest guidance, which revealed a weaker-than-expected forecast for the upcoming period. According to InvestingPro data, analyst targets currently range from $240 to $310, with the stock trading near its 52-week low.
Dan Brennan, the analyst from TD Cowen, noted that while Danaher's Bioprocess segment showed a solid performance in the fourth quarter and the guidance for the future looks positive, other areas of the company are experiencing challenges that are affecting both revenue and profit margins. Brennan emphasized that these issues do not alter the core investment thesis for Danaher, which is centered on the company's focus on life sciences, higher margins, and growth potential. The company maintains strong fundamentals with a gross profit margin of nearly 60% and receives a "GOOD" financial health score from InvestingPro, which offers comprehensive analysis through its Pro Research Reports.
The analyst pointed out that two significant headwinds—China's Value Based Procurement impacting Diagnostics and weak US instrument sales—are anticipated to be resolved early in 2025. This resolution is expected to set the stage for a stronger performance in the second half of the year. Consequently, TD Cowen has revised its forecasts for Danaher, with expectations for 2025 to align with the company's guidance and for 2026 to achieve 7% organic growth and 12% EPS growth.
Despite a 10% decline in Danaher's stock value today, Brennan believes that the company's shares still command a valuation premium compared to its peers. The analyst suggests that growing confidence in the resolution of current challenges and a clear path toward high single-digit growth in 2026 are crucial for sustaining this premium valuation. The new price target of $260.00 is based on a 30 times multiple of the projected 2026 earnings, which is a decrease from the previous multiple of 32. Currently trading at a P/E ratio of 42.9x and with a market capitalization of $165 billion, Danaher's detailed valuation metrics and additional insights are available through InvestingPro's extensive financial analysis tools.
In other recent news, Danaher Corporation has seen adjustments in its stock price targets by multiple analyst firms. Stifel has reduced its price target for Danaher to $260, maintaining a Hold rating. This adjustment follows Danaher's conservative stance on its initial 2025 outlook. Similarly, RBC Capital Markets has decreased its price target for Danaher to $277 from $299, while maintaining an Outperform rating. This change was triggered by Danaher's fiscal year 2025 guidance, which projects earnings per share at approximately $7.60, slightly below Wall Street's expectations. BofA Securities has also adjusted its price target for Danaher, reducing it to $265 from the previous $290, but reiterated a Buy rating.
In terms of mergers and acquisitions, Danaher's stock observed an uptick following robust financial results from German life sciences company Sartorius AG (ETR:SATG). Furthermore, Guggenheim initiated coverage on Danaher shares with a Buy rating and a price target of $275, expecting a return to high single-digit revenue growth in the coming quarters.
In other company news, the U.S. Commerce Department announced new export controls on biotechnology equipment, leading to a decline in Danaher and other related stocks. These are the recent developments for Danaher Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.